Verde Science (VRCI) Aeroponic Marijuana Growing

New Post Public Reply Private Reply Replies (0) Message Board
Jerseyfish

Verde Science (VRCI) Aeroponic Marijuana Growing Solutions.
Verde Science (VRCI) Aeroponic Marijuana Growing Solutions.
View this email online if it doesn't display correctly
Verde Science, Inc.
(OTC: VRCI)
Verde Science, Inc. is focused on Medical Marijuana Research and Development.

Verde also provides advisory services, quality assurance, and aeroponic growing systems in the burgeoning Medical Marijuana industry to established, licensed growers throughout Canada.

"New India based R&D Staff enables us to begin on research and clinical trials in India, which at the moment are on hold pending licensing in Canada."

"This gives Verde a huge advantage.”
Assisting the Industry to Produce Premium Medical Marijuana and Cannabinoid Formulations Through Advanced Research and Development
Verde Science, Inc. (OTCQB: VRCI) has identified and developed relationships with leading research and production experts in the rapidly expanding medical marijuana industry.

The company is focused on providing an array of research and development, cannabinoid formulations, and technical services including aeroponic technology for its industry client base to enable them to produce the highest quality, greatest yield medicinal marijuana.

Verde Science supports leading-edge research to continually provide clients with a premium, branded line of medical marijuana products. Our highly experienced team is deploying state-of-the-art research and development to take a meaningful market share of the Canadian Medical Marijuana marketplace to help address a large number of health care issues.

We are being meticulous, measured and diligent as we move forward with an absolute focus on compliance while helping clients offer the patient community unsurpassed, fully integrated, holistic health care products.

The company is focused on research and development, cannabinoid formulations, and technical services including aeroponic technology for its industry client base to enable them to produce the highest quality, greatest yield medicinal marijuana.
Medicinal Marijuana
Verde Science has assembled a highly experienced, well-funded team that will deploy state-of-the-art research technology and the superior growing methodology of aeroponics to enter and take a meaningful market share. The company is launching its THC Pharmaceutical Development Program by executing a comprehensive research program which involves developing custom ?formulations preparing protocols for clinical trials which will initially be conducted through its partnership alliance with a pharmaceutical company in Mumbai, India.

Verde Science plans to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs for a variety of ailments including chronic pain, inflammation, migraines, seizures related to epilepsy, nausea associated with cancer treatment, and numerous others. The company then plans to then conduct clinical trials in Canada after it obtains its Canadian R&D license.

With consistent, highly efficient production of clean product with no pesticides grown in environmentally friendly surroundings using recycled water, and custom cannabinoid formulations with novel delivery mechanisms, Canada will soon be introduced to the “Tesla” of medical marijuana.

Marijuana Grown with Aeroponics
Aeroponics is the process of growing plants in an air or mist environment without the use of soil or an aggregate medium (known as geoponics). The word “aeroponic” is derived from the Greek meanings of aero- (air) and ponos (labor). Aeroponic culture differs from conventional hydroponics, aquaponics, and in-vitro (plant tissue culture) growing. Unlike hydroponics, which uses a liquid nutrient solution as a growing medium and essential minerals to sustain plant growth; or aquaponics, which uses water and fish waste, aeroponics is conducted without a growing medium. Because water is used in aeroponics to transmit nutrients, it is sometimes considered a type of hydroponics.
Verde Science, Inc. expansion of its Research and Development capabilities with the addition of its newest alliance partners, Dr. Ratnesh Jain and Dr. Prajatka Dandekar Jain
Verde Science Strengthens Scientific Team

Oct 02, 2014 (ACCESSWIRE via COMTEX)

Verde Science, Inc. (VRCI-OTCQB) a Medical Marijuana Research and Development Company, is pleased to announce the expansion of its Research and Development capabilities with the addition of its newest alliance partners, Dr. Ratnesh Jain and Dr. Prajatka Dandekar Jain, both of whom earned their Ph.D.'s in Pharmacology from the Institute of Chemical Technology, a Mumbai, India based University with a research focus along the entire spectrum of Chemical Engineering. Dr. Ratnesh Jain has investigated the development and design of novel drug delivery mechanisms which we believe will have significant applications in the nascent field of Medical Marijuana treatment. This could also be applied to clinical trials aimed at determining proper dosing and drug formulations for various specific medical issues.

Dr. Prajakta Dandekar Jain is an Assistant Professor of Pharmaceutical Technology at the Institute of Chemical Technology. In addition to research into novel drug delivery systems, she has also focused much of her research on nanoparticles, which will have particular relevance in the study of medical uses of THC and cannabinoids, and nanoparticles of hemp. Harp Sangha, Verde's Chairman and CEO commented, "The addition of Drs. Jain to our current in-house R&D staff in Canada is going to be an immediate boost to our research program. It enables us to begin on research and clinical trials in India, which at the moment are on hold pending licensing in Canada. This gives Verde a huge advantage."

Verde's Research and Development Program will focus on developing custom medicinal formulations from cannabinoids and THC compounds for the treatment of specific issues such as migraines, glaucoma, loss of appetite from cancer therapies, and numerous other medical issues. Verde also plans to alpha test innovate growing technologies in India as part of the company's initiatives. (A more extensive background statement for the Drs. Jain is available on the Verde Science website: VerdeScienceInc.com
“The addition of Drs. Jain and Jain to our current in-house R&D staff in Canada is going to be an immediate boost to our research program. It enables us to begin on research and clinical trials in India, which at the moment are on hold pending licensing in Canada. This gives Verde a huge advantage.”
~Harp Sangha, Verde’s Chairman and CEO
Top Notch India Based R&D Staff could be a Huge Game Changer for VRCI!

"This gives Verde a huge advantage”
Verde Science, Inc.
(OTC: VRCI)

To Learn more about Verde Science visit the company website at:
VerdeScienceInc.com

Verde Science, Inc. (VRCID) Stock Research Links

VRCID Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

MediaAlpha Set for Q3 2024 Financial Results Presentation

Updated Category News Views 77

MediaAlpha's Upcoming Financial Report Announcement MediaAlpha, Inc. (NYSE: MAX), based in Los Angeles, has exciting news for its investors and stakeholders. The company is gearing up to announce its financial results for the third quarter of 2024 on an upcoming Wednesday. This announcement will take place after the market closes, providing important insights into the...

Continue Reading
BigID Launches Innovative AI Data Access Control Solutions

Updated Category News Views 218

BigID Launches Innovative Solutions for AI Data Access Control Organizations are increasingly leveraging technology in ways that enhance workflows while prioritizing data security. BigID, a leader in the realm of data security and privacy, has introduced a groundbreaking method to prevent unauthorized access to sensitive information in Artificial Intelligence (AI)...

Continue Reading
Latigo Biotherapeutics Secures $150 Million to Innovate Pain Management

Updated Category News Views 442

Latigo Biotherapeutics Secures Major Funding for Pain Relief Advancement Latigo Biotherapeutics, a clinical-stage biotechnology firm dedicated to creating leading non-opioid pain management solutions, has officially closed a substantial $150 million in Series B financing. This funding round aims to push forward the development of their innovative Nav1.8 inhibitor...

Continue Reading
WisdomTree Moves Forward with UK Equity Income Shift

Updated Category News Views 119

WisdomTree's Strategic Shift in UK Equity Income In a significant move, the Directors of WisdomTree Issuer ICAV have officially announced plans to delist the WisdomTree UK Equity Income UCITS ETF. This decision comes as the company aims to merge its focus towards investing in UK Quality Dividend Growth strategies. The shares of this Sub-Fund will no longer be available...

Continue Reading
Avista Foundation's 2024 Grants: Supporting Community Initiatives

Updated Category News Views 384

Avista Foundation's Generous Grants in 2024 In its recent fourth-quarter granting cycle, the Avista Foundation has showcased its unwavering commitment to enhancing community welfare. The foundation distributed a remarkable total of $54,650 to 21 nonprofit organizations across various initiatives aimed at promoting environmental sustainability and enriching arts and...

Continue Reading